Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma’s CannEpil®, a compounded cannabinoid formulation, has shown promise in seizure management, demonstrating potent efficacy and a favorable safety profile in early Australian and Irish trials. With lower doses required compared to CBD-only treatments and high retention rates, CannEpil® is advancing through clinical development, including preclinical studies and upcoming trials, aiming for market authorization. The product is gaining international traction, already accessible in Ireland and the UK under special programs, and is initiating the pre-IND process for potential entry into the US market.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
